42,076 Shares of Summit Therapeutics PLC $SMMT Acquired by Mirae Asset Global Investments Co. Ltd.

Posted by Brian Himes on Nov 9th, 2026

Mirae Asset Global Investments Co. Ltd. purchased a new stake in Summit Therapeutics PLC (NASDAQ:SMMT – Free Report) in the third quarter, Holdings Channel.com reports. The firm purchased 42,076 shares of the company’s stock, valued at approximately $712,000.

A number of other hedge funds have also recently bought and sold shares of SMMT. ProShare Advisors LLC raised its position in shares of Summit Therapeutics by 8.7% in the 3rd quarter. ProShare Advisors LLC now owns 27,660 shares of the company’s stock valued at $468,000 after purchasing an additional 2,209 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Summit Therapeutics by 10.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 147,158 shares of the company’s stock worth $2,412,000 after buying an additional 13,631 shares in the last quarter. Simplify Asset Management Inc. bought a new stake in shares of Summit Therapeutics in the third quarter worth $8,626,000. Oppenheimer & Co. Inc. bought a new stake in shares of Summit Therapeutics in the third quarter worth $257,000. Finally, Kingswood Wealth Advisors LLC acquired a new stake in Summit Therapeutics in the third quarter valued at $482,000. Institutional investors and hedge funds own 4.61% of the company’s stock.

Summit Therapeutics Price Performance

SMMT stock opened at $16.33 on Monday. Summit Therapeutics PLC has a 1-year low of $12.07 and a 1-year high of $29.23. The firm has a fifty day moving average price of $16.25 and a two-hundred day moving average price of $16.15. The firm has a market cap of $13.06 billion, a price-to-earnings ratio of -15.26 and a beta of -1.49.

Summit Therapeutics News Summary

Here are the key news stories impacting Summit Therapeutics this week:

Positive Sentiment: HC Wainwright maintained its Buy rating and raised its earnings estimates across several periods, forecasting narrower losses for FY2026 (a loss of $1.04 per share versus $1.06 previously) and FY2027 (a loss of $0.98 versus $1.05). Its quarterly estimates were also generally revised toward smaller losses. These are forecasts, not reported results. Summit Therapeutics analyst estimate report
Positive Sentiment: A separate report grouped Summit among healthcare stocks analysts are bullish on, reinforcing the favorable analyst tone. Analysts Are Bullish on These Healthcare Stocks
Neutral Sentiment: Another article notes SMMT moved above its 200-day moving average, a potentially constructive technical signal, but its headline raises the question of selling and provides no clear investment recommendation. Summit Therapeutics stock breaks above 200-day moving average

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Summit Therapeutics in a research note on Tuesday, September 22nd. Jefferies Financial Group restated a “buy” rating on shares of Summit Therapeutics in a research note on Monday, October 26th. The Goldman Sachs Group set a $41.00 target price on shares of Summit Therapeutics and gave the company a “buy” rating in a research note on Tuesday, September 29th. Barclays increased their price target on shares of Summit Therapeutics from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 1st. Finally, Guggenheim reiterated a “buy” rating on shares of Summit Therapeutics in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $28.61.

Read Our Latest Stock Report on Summit Therapeutics

About Summit Therapeutics

(Free Report)

Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer.

Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.